Investor Presentation: First Nine Months of 2020
120
Investor presentation
First nine months of 2020
Providing access to affordable care is a key priority for Novo
Nordisk
Novo NordiskⓇ
Product quality and patient safety is material
30.0 million
patients reached
with Diabetes care
products
2.9 million people
with diabetes
treated at cost
below USD 0.12
per day
Access to insulin commitment strengthened
Novo Nordisk guarantees to make low-priced human insulin available to the
world's poorest countries and selected organisations providing
humanitarian relief
105 million DKK
donations to World
Diabetes Foundation
and Novo Nordisk
Haemophilia Foundation
4 product recalls
O failed
inspections
76 low- and
middle-income
countries covered
Note: Above is 2019 year-end data. Full social statements to be found in Novo Nordisk Annual Report 2019
1 This reflects the price to governments in the 'Access to insulin commitment'.
目
As of 1 August, 2020
ceiling price is
reduced from 4 to 3
USD/vial1View entire presentation